PO-01-092 FIRST RESULTS FROM PVI WITH A NOVEL RADIOFREQUENCY BALLOON-CATHETER FOR THE TREATMENT OF PAROXYSMAL AND PERSISTENT ATRIAL FIBRILLATION

For patients with symptomatic atrial fibrillation (AF) pulmonary vein isolation (PVI) has evolved to the standard of care. minimization reconnection, for reduction complications and improvement PVI efficiency, also in a timely manner, many catheter technologies have been developed already. A new ablation modality that regard is radiofrequency balloon-catheter (RF-BC). However evidence concerning this technology sparse. Evaluation procedural data, safety profile clinical outcome using RF-BC PVI. Since September 2021 first-time (HELIOSTAR™, Biosense Webster) included our ongoing monocentric register study. Esophageal temperature (ET) phrenic nerve (PN) monitoring performed during energy delivery. In case ET exceedence above 42 degree Celsius an esophagogastroscopy (EGD) conducted. Follow-up scheduled 3, 6, 12 24 months post recurrence. Until now 130 individuals (age [y]: 69 ± 9.8, female: 37.7%, paroxysmal AF 64.6%, CHA2DS2-VASc 4 preserved ejection fraction 56.2%, left diameter [mm] 45 8.3) Mean duration (skin-to-skin) was 88 (± 35) minutes. Single-shot-isolation possible 80,2% 516 treated PVs. On average five deliveries per patient had applied. Fortunately no pericardial tamponade, stroke fatalities occurred. Nevertheless PN palsy detected one patient. Luckily it resolved completely within 48h. Due 6 20 esophageal lesions EGD. All spontaneously. Recurrence-free-survival after 73.0% Kaplan-Meier analysis if blanking period applied, 94.0% 90-day period. Thanks only energy-delivery most cases, seems be very efficient tool. But more importantly safe one.